Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.73% of ...
CantorFitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($6.11) per share for the year, up from their previous estimate of ($6.21).